These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22250438)

  • 1. [Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].
    Imai E
    Nihon Naika Gakkai Zasshi; 2011 Nov; 100(11):3386-92. PubMed ID: 22250438
    [No Abstract]   [Full Text] [Related]  

  • 2. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.
    Imai E; Ito S; Haneda M; Chan JC; Makino H;
    Hypertens Res; 2006 Sep; 29(9):703-9. PubMed ID: 17249526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
    Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
    Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
    Imai E; Haneda M; Yamasaki T; Kobayashi F; Harada A; Ito S; Chan JC; Makino H
    Hypertens Res; 2013 Dec; 36(12):1051-9. PubMed ID: 24026038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
    Abe M; Oikawa O; Okada K; Soma M
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
    Mizuno M; Sada T; Kato M; Fukushima Y; Terashima H; Koike H
    J Cardiovasc Pharmacol; 2006 Oct; 48(4):135-42. PubMed ID: 17086090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 9. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.
    Utsumi K; Yasuda F; Watanabe Y; Higo S; Hirama A; Fujita E; Ueda K; Mii A; Kaneko T; Mishina M; Iino Y; Katayama Y
    Clin Chim Acta; 2012 Jan; 413(1-2):348-9. PubMed ID: 21983097
    [No Abstract]   [Full Text] [Related]  

  • 11. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.
    Catalá-López F; Martín-Serrano G; Maciá MA; Montero D
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):678-9; author reply 679-80. PubMed ID: 22608016
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes: ROADMAP: the road to renoprotection?
    Roscioni SS; Heerspink HJ; de Zeeuw D
    Nat Rev Nephrol; 2011 May; 7(8):427-8. PubMed ID: 21610679
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.
    Song HF; Chen JF; Sun NL; Li HW
    Chin Med J (Engl); 2011 Feb; 124(4):562-7. PubMed ID: 21362282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
    Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan, microalbuminuria, and type 2 diabetes.
    Fioretto P; Mauer M
    N Engl J Med; 2011 Jun; 364(23):2260-1; author reply 2262-3. PubMed ID: 21651400
    [No Abstract]   [Full Text] [Related]  

  • 19. Olmesartan, microalbuminuria, and type 2 diabetes.
    Yudkin JS; Lehman R
    N Engl J Med; 2011 Jun; 364(23):2260; author reply 2262-3. PubMed ID: 21651401
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.